This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The FDA has announced several guidelines and plans to hold at least one public meeting on digital healthtechnologies (DHTs) to be used in drug clinical trials by the end of the year. Drugdevelopment process questions the reliability and accuracy of DHT products.
Digital HealthTechnologies ( DHTs ) have revolutionized the landscape of clinical trials, particularly in neurology research, by enabling the collection of real-world data outside traditional clinical settings. The use of DHTs in neurology trials produced consistent benefits on many levels.
Koneksa’s innovative digital model aims to address limitations in existing functional status assessments by leveraging digital healthtechnologies (DHTs) for both objective and self-reported outcomes. This is complemented by electronic questionnaires tailored to each concept, ensuring comprehensive data collection.
BASEL, Switzerland–(BUSINESS WIRE)–Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital healthtechnology and develop digital biomarkers for Parkinson’s disease.
This pilot study represents a critical step in leveraging digital healthtechnology to enhance cancer treatment outcomes,” said John Wagner, M.D., The study, led by principal investigator Nitin Ohri, M.D., Chief Medical Officer, Koneksa. “By
Focus on Data and Analytics: Companies with robust data analytics capabilities and insights into patient behaviour will be well-positioned. Regulatory Landscape: Regulatory Clarity: Clearer regulatory frameworks for digital healthtechnologies will foster investor confidence and higher valuations.
In 2025, B2C2B models are poised to become increasingly prominent in healthcare, driven by several key factors: Digital Health Boom: The rapid growth of digital healthtechnologies, such as telehealth, wearable devices, and AI-powered diagnostics, is creating new opportunities for B2C2B companies to reach both patients and healthcare providers.
The Beacon Platform unlocks longitudinal, at-home EEG technology, applies machine-learning algorithms to maximize insights into brain activity, and empowers sponsors with comprehensive data analysis and data visualization capabilities. For more information, visit [link]. For partnership inquiries, visit [link].
The investment adds to a growing list of prominent digital health investors in Europe and the United States, including Nina Capital and Young Sohn, a co-founder of Veeva Systems. The funding speaks to the global nature of pre-approval access and its increasing importance in the drugdevelopment process. “
We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale, provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions.” They can view historic data and forecast future trends. in 2060.
Furthermore, the industry witnessed a decline in the average return on investment (ROI) for R&D to as low as 1.2%, and the peak sales per asset valued just above $350 million, indicating a need to build more efficient drugdevelopment processes with the implementation of newer technologies.
Focus on AI and Data Analytics: US companies will prioritise acquisitions of companies with advanced AI and data analytics capabilities to gain insights into patient data and improve decision-making. Biometric Sensors: Companies developing advanced biometric sensors will be attractive to both tech and healthcare firms.
Elevating Global Patient Access to Clinical Trials through Revolutionary Collaboration and Advanced AI-Driven Technologies NEW YORK–(BUSINESS WIRE)– Massive Bio Inc.,
Despite a history of drugdevelopment failures in the field, recent work provides reason for optimism, showing a possible therapeutic arsenal to limit disease progression at an early stage.
When it comes to incorporating new technology into drugdevelopment and clinical practice, the best place to start is with the patients. Each article opens with an actual clinical case where wearable data was used to care for a patient.
1] [6] Each block typically contains a cryptographic hash of the previous block, [6] a timestamp and transaction data. [7] 7] By design, a blockchain is inherently resistant to modification of the data. Herding a patient’s data from many sources into a single record has always been a lofty goal of digital health.
Wearable devices: These are devices that are worn on the body and can track healthdata such as heart rate, sleep, and activity levels. Telehealth: This is the delivery of healthcare services remotely, using technology such as video conferencing or phone calls. Examples include vaccines, gene therapy, and personalised medicine.
Whether it is in operational delivery, service provision, patient enablement or drug discovery, technology has continued to create wide scale impact as we shift towards a post-pandemic world. Harnessing the potential of data and Artificial Intelligence . We can also use data to predict disease.
The Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS) will create the largest open data platform for ALS research Partnership will enable discovery and development of diagnostic tools, biomarkers, and better treatments NORTH BETHESDA, Md.–(BUSINESS
Digital healthtechnologies (DHT) can collect objective, multi-dimensional data passively and remotely with a limited burden for clinical trial participants, providing a way to capture previously inaccessible insights to support drugdevelopment and commercialization.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content